Lux Peptides

Lux Peptides TIRZ (tirzepatide) research vial, lyophilised powder
Certificate of Analysis for TIRZ (tirzepatide) 20 mg, independent laboratory test report
Certificate of Analysis for TIRZ (tirzepatide) 10 mg, independent laboratory test report
Certificate of Analysis for TIRZ (tirzepatide) 40 mg, independent laboratory test report

TIRZ

Price range: £34.99 through £89.99

Research-grade tirzepatide, supplied as lyophilised powder in 10 mg, 20 mg and 40 mg vials. For laboratory research use only. Not for human or animal consumption.

Shipped by Royal Mail, packed with ice packs to keep your order cool in transit. UK delivery £3.99.

SKU: TR-TIRZ
Category: ,
Brands:

Research reference

TIRZ

Extensive clinical trial data

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. It is supplied as a lyophilised powder for laboratory research applications only.

Molecular information

Type

Dual GIP/GLP-1 receptor agonist

Length

39 amino acids

Formula

C225H348N48O68

Weight

4813.5 g/mol

CAS

2023788-19-2

Form

Lyophilised powder

Vial sizes

10 mg / 20 mg / 40 mg

Classification

Incretin mimetic

Sequence

  • 01Tyr
  • 02Aib
  • 03Glu
  • 04Gly
  • 05Thr
  • 06Phe
  • 07Thr
  • 08Ser
  • 09Asp
  • 10Tyr
  • 11Ser
  • 12Ile
  • 13Aib
  • 14Leu
  • 15Asp
  • 16Lys
  • 17Ile
  • 18Ala
  • 19Gln
  • 20Lys(C20 diacid)
  • 21Ala
  • 22Phe
  • 23Val
  • 24Gln
  • 25Trp
  • 26Leu
  • 27Ile
  • 28Ala
  • 29Gly
  • 30Gly
  • 31Pro
  • 32Ser
  • 33Ser
  • 34Gly
  • 35Ala
  • 36Pro
  • 37Pro
  • 38Pro
  • 39Ser
  • 40NH2

Y[Aib]EGTFTSDYSI[Aib]LDKIAQKAFVQWLIAGGPSSGAPPPS

Research overview

Tirzepatide is built on the native GIP sequence, with changes that give it activity at both the GIP and GLP-1 receptors. A C20 fatty diacid chain on lysine 20 binds albumin and gives a half-life of about five days. Research has examined how combined GIP and GLP-1 receptor activity affects insulin secretion, glucose control, body weight and fat metabolism.

Common research focus areas

  • Dual incretin receptor signalling
  • Glycaemic control models
  • Body weight and adiposity research
  • Lipid metabolism studies

Laboratory research use only

This product is supplied strictly for laboratory research use. It is not a medicine, food, cosmetic, or dietary supplement, and is not for human or animal consumption. Any use outside a documented laboratory research protocol is prohibited.

Handling

For laboratory use, reconstitute with a sterile diluent appropriate to the research protocol, introducing the diluent slowly against the vial wall to minimise peptide degradation. Do not shake.

Published research

  • LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptCoskun T et al. · Molecular Metabolism · 2018 · DiscoveryPMID 30473097
  • Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesFrías JP et al. · New England Journal of Medicine · 2021 · Randomised controlled trialPMID 34170647
  • Tirzepatide Once Weekly for the Treatment of ObesityJastreboff AM et al. · New England Journal of Medicine · 2022 · Randomised controlled trialPMID 35658024

Evidence status

Tirzepatide has been studied in large randomised controlled trials and is licensed as a prescription medicine under specific brand names. The material supplied here is a research-grade compound, is not a licensed medicine, and is intended for laboratory research only.

Additional information

Vial Size

10 mg, 20 mg, 40 mg

Related products